Antibiotic resistance of pathogens causing community-acquired urinary tract infections in pregnant women with diabetes mellitus

Abstract

BACKGROUND: Urinary tract infections are among the most common infectious diseases in women and are the most frequent cause of infectious complications of pregnancy, especially in pregnant women with type 1 diabetes mellitus. For adequate treatment of urinary tract infections in pregnant women with type 1 diabetes mellitus, it is requisite to regularly monitor antimicrobial resistance of uropathogens in order to update empirical schemes of antibacterial therapy.

AIM: The aim of this study was to determine the spectrum of uropathogens and the activity of antibacterial drugs against pathogens of community-acquired urinary tract infections in pregnant women with type 1 diabetes mellitus or without diabetes mellitus.

MATERIALS AND METHODS: We analyzed 91 strains obtained from pregnant women with or without type 1 diabetes mellitus. The sensitivity of microorganisms to all antibacterial drugs was evaluated by the disk diffusion method.

RESULTS: In the group of pregnant women with type 1 diabetes mellitus in the etiological structure of uropathogens, enterobacteria accounted for 84.8%, Escherichia coli (71.7%) and Klebsiella spp. (13.0%) being the most common. In the group of pregnant women without diabetes mellitus in the structure of uropathogens, enterobacteria accounted for 75.6%, while E. coli was the causative agent of urinary tract infections in 62.2% of women and Klebsiella spp. in 11.1%. Gram-positive uropathogens were isolated much less frequently. In the group of pregnant women with type 1 diabetes mellitus, piperacillin/tazobactam, carbapenems, nitrofurantoin, and amikacin (100%), as well as fosfomycin and gentamicin (97%), had the maximum antibacterial activity against E. coli. The sensitivity of E. coli to various cephalosporins varied in the range of 84.9–90.9%. In the group of pregnant women without diabetes mellitus and with urinary tract infections, the highest E. coli sensitivity rates were observed for piperacillin/tazobactam, carbapenems, fosfomycin, nitrofurantoin, gentamicin, and amikacin (100%). E. coli sensitivity to second and third generation cephalosporins varied in the range of 75.0–82.1%, and it was 96.4% to cefepime. Ampicillin and amoxicillin/clavulanate demonstrated the least activity against E. coli in the two study groups. The rate of extended spectrum beta-lactamase production by uropathogenic enterobacteria in pregnant women with type 1 diabetes mellitus was 15.8% of the strains, and in pregnant women without diabetes mellitus, it was 18.1%.

CONCLUSIONS: There were no significant differences in the activity of antibacterial drugs against the pathogens of community-acquired urinary tract infections in pregnant women with or without diabetes mellitus.

Keywords

pregnancy / urinary tract infections / diabetes mellitus / uropathogenic bacteria / antibacterial resistance

References

[1] Werter DE, Kazemier BM, van Leeuwen E, et al. Diagnostic work-up of urinary tract infections in pregnancy: study protocol of a prospective cohort study. BMJ Open. 2022;12(9). DOI: 10.1136/bmjopen-2022-063813

[2] Werter D.E., Kazemier B.M., van Leeuwen E., et al. Diagnostic work-up of urinary tract infections in pregnancy: study protocol of a prospective cohort study // BMJ Open. 2022. Vol. 12. No. 9. DOI: 10.1136/bmjopen-2022-063813

[3] Jeyabalan A, Lain KY. Anatomic and functional changes of the upper urinary tract during pregnancy. Urol Clin North Am. 2007;34(1):1–6. DOI: 10.1016/j.ucl.2006.10.008

[4] Jeyabalan A., Lain K.Y. Anatomic and functional changes of the upper urinary tract during pregnancy // Urol. Clin. North. Am. 2007. Vol. 34. No. 1. P. 1–6. DOI: 10.1016/j.ucl.2006.10.008

[5] Nikiforovsky NK, Stepankova EA, Suhorukova AO. Urinary tract infections in pregnancy. Siberian Scientific Medical Journal. 2020;40(5):18–23. (In Russ.). DOI: 10.15372/SSMJ20200502

[6] Никифоровский Н.К., Степанькова Е.А., Сухорукова А.О. Инфекции мочевыводящих путей у беременных // Сибирский научный медицинский журнал. 2020. Т. 40. № 5. С. 18–23. DOI: 10.15372/SSMJ20200502

[7] Bolotskaya LL, Efremova IV, Suntsov YuI. Specific features of pregnancy in patients with type 1 diabetes in the prepubertal period. Results of a 15-year long clinical observation. Diabetes Mellitus. 2009;(4):28–31. (In Russ.)

[8] Болотская Л.Л., Ефремова Н.В., Сунцов Ю.И. Особенности течения беременности у пациенток с дебютом сахарного диабета 1 типа в препубертатный период. Данные 15-летнего клинического наблюдения // Сахарный диабет. 2009. № 4. С. 28–31.

[9] de Lastours V, Foxman B. Urinary tract infection in diabetes: epidemiologic considerations. Curr Infect Dis Rep. 2014;16(1):389. DOI: 10.1007/s11908-013-0389-2

[10] de Lastours V., Foxman B. Urinary tract infection in diabetes: epidemiologic considerations // Curr. Infect. Dis. Rep. 2014. Vol. 16. No. 1. P. 389. DOI: 0.1007/s11908-013-0389-2

[11] Alekseenko IV, Ivanova LA. Modern view on the problem urinary tract infection in Pregnant women with type 1 diabetes. Mezhdunarodnyi zhurnal prikladnykh i fundamental’nykh issledovanii. 2016;12(7):1174–1179. (In Russ.).

[12] Алексеенко И.В., Иванова Л.А. Современный взгляд на проблему инфекций мочевыводящих путей у беременных с сахарным диабетом 1 типа // Международный журнал прикладных и фундаментальных исследований. 2016. № 12. Ч. 7. С. 1174–1179.

[13] Perepanova TS, Kozlov RS, Rudnov VA, et al. Antimikrobnaya terapiya i profilaktika infektsii pochek, mochevyvodyashchikh putei i muzhskikh polovykh organov. Federal’nye klinicheskie rekomendatsii. Moscow; 2017.

[14] Перепанова Т.С., Козлов Р.С., Руднов В.А., и др. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Федеральные клинические рекомендации. Москва, 2017.

[15] Bonkat G, Bartoletti R, Bruyère F et al. EAU Guidelines on Urological Infections. 2022 [cited 2022 Dec 21]. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urological-Infections-2022.pdf

[16] Bonkat G., Bartoletti R., Bruyère F., et al. EAU Guidelines on urological Infections. 2022 [дата обращения 21.12.2022]. Доступно по ссылке: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urological-Infections-2022.pdf

[17] Palagin IS, Sukhorukova MV, Dekhnich AV, et al. “DARMIS-2018” Study Group. Antimicrobial resistance of pathogens causing community-acquired urinary tract infections in Russia: results of the multicenter study “DARMIS-2018”. Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(2):134–146. (In Russ.). DOI: 10.36488/cmac.2019.2.134-146

[18] Палагин И.С., Сухорукова М.В., Дехнич А.В., и др.; Исследовательская группа «ДАРМИС-2018». Антибиотикорезистентность возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового исследования «ДАРМИС-2018» // Клиническая микробиология и антимикробная химиотерапия. 2019. Т. 21. № 2. С. 134–146. DOI: 10.36488/cmac.2019.2.134-146

[19] Akash MSH, Rehman K, Fiayyaz F, et al. Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies. Arch Microbiol. 2020;202(5):953–965. DOI: 10.1007/s00203-020-01818-x

[20] Akash M.S.H., Rehman K., Fiayyaz F., at al. Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies // Arch. Microbiol. 2020. Vol. 202. No. 5. P. 953–965. DOI: 10.1007/s00203-020-01818-x

[21] Malmartel A, Ghasarossian C. Bacterial resistance in urinary tract infections in patients with diabetes matched with patients without diabetes. J Diabetes Complications. 2016;30(4):705–709. DOI: 10.1016/j.jdiacomp.2016.01.005

[22] Malmartel A., Ghasarossian C. Bacterial resistance in urinary tract infections in patients with diabetes matched with patients without diabetes // J. Diabetes Complications. 2016. Vol. 30. No. 4. P. 705–709. DOI: 10.1016/j.jdiacomp.2016.01.005

[23] Infekciya mochevyh putej pri beremennosti. Klinicheskie rekomendacii. 2021. (In Russ.) [cited 2022 Dec 21]. Available from: https://roag-portal.ru/recommendations_obstetrics

[24] Инфекция мочевых путей при беременности. Клинические рекомендации. 2021 [дата обращения 21.12.2022]. Доступно по ссылке: https://roag-portal.ru/recommendations_obstetrics

[25] Lokshin KL, Shirshov VN, Popko AS, et al. The current state of antibiotic resistance and the composition of pathogens of urinary tract infections in pregnant women. Vestnik urologii. 2018;6(2):13–20. (In Russ.). DOI: 10.21886/2308-6424-2018-6-2-13-20

[26] Локшин К.Л., Ширшов В.Н., Попко А.С., и др. Современное состояние антибиотикорезистентности и состав возбудителей инфекций мочевыводящих путей у беременных // Вестник урологии. 2018. Т. 6. №. 2. С. 13–20. DOI: 10.21886/2308-6424-2018-6-2-13-20

[27] Meier S, Weber R, Zbinden R, et al. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39(4):333–340. DOI: 10.1007/s15010-011-0132-6

[28] Meier S., Weber R., Zbinden R., at al. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy // Infection. 2011. Vol. 39. No. 4. P. 333–340. DOI: 10.1007/s15010-011-0132-6

[29] Paudel S, John PP, Poorbaghi SL, et al. Systematic review of literature examining bacterial urinary tract infections in diabetes. J Diabetes Res. 2022;2022. DOI: 1155/2022/3588297

[30] Paudel S., John P.P., Poorbaghi S.L., at al. Systematic review of literature examining bacterial urinary tract infections in diabetes // J. Diabetes Res. 2022. Vol. 2022. DOI: 10.1155/2022/3588297

[31] Ny S, Edquist P, Dumpis U, et al. Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia. J Glob Antimicrob Resist. 2019;17:25–34. DOI: 10.1016/j.jgar.2018.11.004

[32] Ny S., Edquist P., Dumpis U., et al. Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia // J. Glob. Antimicrob. Resist. 2019. Vol. 17. P. 25–34. DOI: 10.1016/j.jgar.2018.11.004

RIGHTS & PERMISSIONS

Khusnutdinova T.A., Shipitsyna E.V., Krysanova A.A., Savicheva A.M., Kapustin R.V.